WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
maximize
Machine translation
1. (WO2014169007) COMBINATION THERAPEUTIC NANOPARTICLES
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

What is claimed is:

1. Use of a nanoparticle comprising a chemotherapeutic agent and an antiinflammatory agent in the manufacture of a medicament for the treatment of prostate cancer.

2. A use according to claim 1, wherein the nanoparticle comprises a hydrophilic core and a hydrophilic layer surrounding the core.

3. A use according to claim 1 or claim 2, wherein the chemotherapeutic agent and the anti-inflammatory agent are attached to the core.

4. A use according to any one of the preceding claims, wherein the chemotherapeutic agent is cisplatin.

5. A use according to any one of the preceding claims, wherein the antiinflammatory agent is aspirin.

6. A use according to any one of the preceding claims, wherein the prostate cancer is castration resistant prostate cancer.

7. A use according to any one of the preceding claims, wherein the nanoparticle is more cytotoxic to prostate cancer cells than a combination of a comparable dose of the free chemotherapeutic agent and the free anti-inflammatory agent.

8. A method for treating prostate cancer in a subject in need thereof, comprising:

administering a therapeutically effective amount of a nanoparticle comprising a chemotherapeutic agent and an anti-inflammatory agent to the subject.

9. A method according to claim 8, wherein the nanoparticle comprises a hydrophilic core and a hydrophilic layer surrounding the core.

10. A method according to claim 8 or claim 9, wherein the chemotherapeutic agent and the anti-inflammatory agent are attached to the core.

1 1. A method according to any one of claims 7-10, wherein the chemotherapeutic agent is cisplatin.

12. A method according to any one of claims 7-11, wherein the anti-inflammatory agent is aspirin.

13. A method according to any one claims 7-12, wherein the prostate cancer is castration resistant prostate cancer.

14. A use according to any one claims 7-13, wherein the nanoparticle is more cytotoxic to prostate cancer cells than a combination of a comparable dose of the free chemotherapeutic agent and the free anti-inflammatory agent.

15. A nanoparticle, comprising:

a hydrophobic nanoparticle core, wherein the hydrophobic polymer that forms at least a part of the core is selected from the group consisting of a polymer comprising polylactic acid (PLA) and a polymer comprising polylactic-co-glycolic acid (PLGA);

a hydrophilic layer surrounding the core, wherein the hydrophilic polymer moiety is attached to the core via a hydrophobic polymer moiety that forms at least a part of the core;

an anti-inflammatory agent attached to the core; and

a chemotherapeutic agent attached to the core.

16. A nanoparticle according to claim 15, wherein the anti-inflammatory agent is a corticosteroid or a non-steroidal anti-inflammatory drug.

17. A nanoparticle according to claim 15, the anti-inflammatory agent is aspirin.

18. A nanoparticle according to claim 15, the anti-inflammatory agent is prednisone.

19. A nanoparticle according to any one of claims 15-18, further comprising a prostate cancer targeting moiety.

20. A nanoparticle according to claim 19, wherein the targeting moiety is a moiety configured to selectively bind to a prostate specific membrane antigen.

21. A nanoparticle according to claim 19, wherein the targeting moiety comprises a peptide having an amino acid sequence of WQPDTAHHWATL (SEQ ID NO: 1) or a prostate specific membrane antigen binding fragment thereof.

A nanoparticle according to any one of claims 15-21, wherein the antiinflammatory agent is conjugated to a polymer forming at least a part of the hydrophobic core.

23. A nanoparticle according to any one of claims 15-22, wherein the chemotherapeutic agent is conjugated to a polymer forming at least a part of the hydrophobic core.

A nanoparticle according to claim 23, wherein the polymer to which the antiinflammatory agent is conjugated is the polymer to which the chemotherapeutic agent is conjugated.

A nanoparticle according any one of claims 15-24, further compris inhibitor of bone resorption.

A nanoparticle according claim 25, wherein the inhibitor of bone resorption pamidronate.

27. Use of a nanoparticle according any of claims 15-25 for treating a subject in need thereof.

28. A nanoparticle, comprising:

a hydrophobic nanoparticle core, wherein the hydrophobic polymer that forms at least a part of the core is selected from the group consisting of a polymer comprising polylactic acid (PLA) and a polymer comprising polylactic-co-glycolic acid (PLGA);

a hydrophilic layer surrounding the core, wherein the hydrophilic polymer moiety is attached to the core via a hydrophobic polymer moiety that forms at least a part of the core;

an inhibitor of bone resorption attached to the core; and

a chemotherapeutic agent attached to the core.

29. A compound selected from the group consisting of:



, and